Osteoporosis International

, Volume 24, Issue 1, pp 245–252 | Cite as

Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study

Original Article



Bisphosphonate (BP) users have decreased mortality, but this could be due to channeling bias. National healthcare data on hip fracture showed lower mortality in patients who were treated prior to fracture or began treatment after fracture. Reduced mortality after only one prescription filled points to the importance of patient factors.


Use of bisphosphonates has been found to be associated with decreased mortality even when adjusted for sex, frailty, bone mineral density and comorbidity, but BP may chiefly be initiated in patients with osteoporosis whose life expectancy is judged to be good. Our aim was to investigate the association between BP initiated before or after a hip fracture with mortality, and any modifying effects of comorbid conditions and recurrent fracture.


This register-based cohort study used prescription and mortality information for Danish patients born ≤1945 experiencing a hip fracture between 1/Jan/1999 and 31/Dec/ 2002 (N = 42,076). Patients who began BP after hip fracture were compared with hip fracture patients who remained alive at the time when their matched index case began treatment.


Patients who used BP prior to their hip fracture (4.6 %) had significantly lower 3-month mortality (adjusted odds ratio, OR, 0.68; 0.59–0.77). Patients who began BP after the fracture (2.6 %) had significantly decreased mortality, both for patients who filled only one prescription (adjusted hazard ratio, HR 0.84; 0.73–0.95) and for patients who filled multiple prescriptions HR 0.73 (0.61–0.88). There was a significant interaction by gender with no significant risk reduction in men.


This national dataset shows significantly and substantially improved survival in women who receive BP before or after their hip fracture. However, the observation of a reduction in mortality in patients who filled only one prescription for a BP suggests that patient factors may account for a considerable part of the survival advantage observed with BPs.


Adherence Epidemiology Hip fracture Mortality Osteoporosis 


  1. 1.
    Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153–159PubMedCrossRefGoogle Scholar
  2. 2.
    Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  3. 3.
    Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, Parker MJ, Payne BV, Rushton N (1995) Differences in mortality after fracture of hip: the East Anglian audit. BMJ 310:904–908PubMedCrossRefGoogle Scholar
  4. 4.
    Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture—effect of pre-morbid and postfracture complications. Osteoporos Int 18:1538–1593Google Scholar
  5. 5.
    Cree MW, Juby AG, Carriere KC (2003) Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 14:722–727PubMedCrossRefGoogle Scholar
  6. 6.
    Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390PubMedGoogle Scholar
  7. 7.
    Kannegaard PN, Van Der Mark S, Eiken P, Abrahamsen B (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203–209PubMedCrossRefGoogle Scholar
  8. 8.
    Roche JJ, Wenn RT, Sahota O, Moran CG (2005) Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 331:1374PubMedCrossRefGoogle Scholar
  9. 9.
    Center JR, Bliuc D, Nguyen ND, Nguyen TV, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014PubMedCrossRefGoogle Scholar
  10. 10.
    Sambrook PN, Cameron JS, Chen CJ, March LM, Simpson JM, Cumming RG, Seibel MJ (2010) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556PubMedCrossRefGoogle Scholar
  11. 11.
    Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRefGoogle Scholar
  12. 12.
    Boufous S, Finch CF, Lord SF (2004) Incidence of hip fracture in New South Wales: are our efforts having effect? MJA 180:623–626PubMedGoogle Scholar
  13. 13.
    Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ, Sambrook PN (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5 year study. J Bone Miner Res 25:866–872PubMedGoogle Scholar
  14. 14.
    Vestergaard P, Rejnmark L, Mosekilde L (2009) Loss of life years after a hip fracture: effects of age and sex. Acta Orthop 80:525–530PubMedCrossRefGoogle Scholar
  15. 15.
    Szulc P, Maurice C, Marchand F, Delmas PD (2009) Increased bone resorption is associated with higher mortality in community-dwelling men > 50 years of age: the MINOS study. J Bone Miner Res 24:1116–1124PubMedCrossRefGoogle Scholar
  16. 16.
    Sambrook PN, Chen CJ, March L, Cameron ID, Cumming RG, Lord SR, Simpson JM, Seribel MJ (2006) High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21:549–555PubMedCrossRefGoogle Scholar
  17. 17.
    Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Picentini P, Rocci L, Manavalan JS, Tonini G, Poccia F (2009) In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58:31–38PubMedCrossRefGoogle Scholar
  18. 18.
    Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G, Ingels J, Postlethwaite AE (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371–380, OKPubMedCrossRefGoogle Scholar
  19. 19.
    Fraser L, Vogt KN, Adachi JD, Thabane L (2011) Fracture risk associated with continuation versus discontinuation of bisphophonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag 7:157–166PubMedCrossRefGoogle Scholar
  20. 20.
    Adachi JD, Josse RG, Graham R, Russell G (2011) If you don’t take it—it can’t work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag 7:181–198PubMedCrossRefGoogle Scholar
  21. 21.
    Curtis JR, Larson JJC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Suzanne J, Safford M, Solomon DH, LaCroix AZ (2011) Placebo adherence, clinical outcomes, and mortality in the Women’s Health Initiative Randomized Hormone Therapy trials. Med Care 49:427–435PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  1. 1.Department of Medicine and Endocrinology FGentofte HospitalHellerupDenmark
  2. 2.Department of Cardiology, Nephrology and EndocrinologyHillerød HospitalHillerødDenmark
  3. 3.Odense Patient Data Exploratory Network (OPEN), Institute of Clinical ResearchSDUOdenseDenmark

Personalised recommendations